SEC Form 4 · accession 0001209191-17-038322
MERRIMACK PHARMACEUTICALS INC · MACK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Peters
Officer — President and CEO · Director
Period of report
Jun 6, 2017
Accepted (ET)
Jun 7, 2017 · 4:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001274792
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.45 | Jun 6, 2017 | A | 2,000,000 | A | — | Jun 5, 2027 | Common Stock | 2,000,000 | 2,000,000 | D |
Explanation of responses
- F1This option vests as to 1/4th of the total number of shares granted on 2/6/18 and an additional 1/16th of the total number of shares granted at the end of each successive three month period thereafter until 2/6/21.